Extension of useful reagent shelf life beyond manufacturers' recommendations

Raymond R. Tubbs, Raymond B Nagle, Kevin Leslie, Norman M. Pettigrew, Jonathan W. Said, David J. Corwin, Robert R. Rickert, Patrick C. Roche

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective. - The College of American Pathologists Cell Markers Committee designed a study to evaluate the use of immunohistochemistry primary antibodies beyond manufacturers' recommended dates. Methods. - Pathologists were asked to save aliquots of primary antibodies during mid-1997 so that by spring 1998 the reagents would be 'outdated' according to manufacturers' recommendations. Three tumors were immunostained both in mid-1997 and early 1998 (using outdated reagents in 1998). Two hundred twenty-one laboratories participated. Patient Samples. - Immunostained materials consisted of an angiomyolipoma immunostained for muscle-specific actin and HMB-45, a melanoma immunostained for S100 protein and HMB-45, and a large cell lymphoma immunostained for common leukocyte antigen and HMB-45. Blocks from the same tumor were used in each instance. Main Outcome Measure. - We compared the immunostaining results as a percentage of laboratories indicating a positive or negative immunohistochemical result between the 1997 and 1998 time points. Results. - Only minor differences were identified for the 221 reporting laboratories in 1998 as compared with those in 1997. Conclusions. - The data suggest review of the Health Care Financing Administration's ruling on extending the useful reagent shelf life beyond manufacturers recommendations. Similar studies using more inherently quantitative methodology are suggested.

Original languageEnglish (US)
Pages (from-to)1051-1052
Number of pages2
JournalArchives of Pathology and Laboratory Medicine
Volume122
Issue number12
StatePublished - 1998

Fingerprint

CD45 Antigens
Angiomyolipoma
Centers for Medicare and Medicaid Services (U.S.)
S100 Proteins
Antibodies
Actins
Melanoma
Lymphoma
Neoplasms
Immunohistochemistry
Outcome Assessment (Health Care)
Muscles
Pathologists

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Tubbs, R. R., Nagle, R. B., Leslie, K., Pettigrew, N. M., Said, J. W., Corwin, D. J., ... Roche, P. C. (1998). Extension of useful reagent shelf life beyond manufacturers' recommendations. Archives of Pathology and Laboratory Medicine, 122(12), 1051-1052.

Extension of useful reagent shelf life beyond manufacturers' recommendations. / Tubbs, Raymond R.; Nagle, Raymond B; Leslie, Kevin; Pettigrew, Norman M.; Said, Jonathan W.; Corwin, David J.; Rickert, Robert R.; Roche, Patrick C.

In: Archives of Pathology and Laboratory Medicine, Vol. 122, No. 12, 1998, p. 1051-1052.

Research output: Contribution to journalArticle

Tubbs, RR, Nagle, RB, Leslie, K, Pettigrew, NM, Said, JW, Corwin, DJ, Rickert, RR & Roche, PC 1998, 'Extension of useful reagent shelf life beyond manufacturers' recommendations', Archives of Pathology and Laboratory Medicine, vol. 122, no. 12, pp. 1051-1052.
Tubbs, Raymond R. ; Nagle, Raymond B ; Leslie, Kevin ; Pettigrew, Norman M. ; Said, Jonathan W. ; Corwin, David J. ; Rickert, Robert R. ; Roche, Patrick C. / Extension of useful reagent shelf life beyond manufacturers' recommendations. In: Archives of Pathology and Laboratory Medicine. 1998 ; Vol. 122, No. 12. pp. 1051-1052.
@article{d523daaff36343ed853f1489f553c6b6,
title = "Extension of useful reagent shelf life beyond manufacturers' recommendations",
abstract = "Objective. - The College of American Pathologists Cell Markers Committee designed a study to evaluate the use of immunohistochemistry primary antibodies beyond manufacturers' recommended dates. Methods. - Pathologists were asked to save aliquots of primary antibodies during mid-1997 so that by spring 1998 the reagents would be 'outdated' according to manufacturers' recommendations. Three tumors were immunostained both in mid-1997 and early 1998 (using outdated reagents in 1998). Two hundred twenty-one laboratories participated. Patient Samples. - Immunostained materials consisted of an angiomyolipoma immunostained for muscle-specific actin and HMB-45, a melanoma immunostained for S100 protein and HMB-45, and a large cell lymphoma immunostained for common leukocyte antigen and HMB-45. Blocks from the same tumor were used in each instance. Main Outcome Measure. - We compared the immunostaining results as a percentage of laboratories indicating a positive or negative immunohistochemical result between the 1997 and 1998 time points. Results. - Only minor differences were identified for the 221 reporting laboratories in 1998 as compared with those in 1997. Conclusions. - The data suggest review of the Health Care Financing Administration's ruling on extending the useful reagent shelf life beyond manufacturers recommendations. Similar studies using more inherently quantitative methodology are suggested.",
author = "Tubbs, {Raymond R.} and Nagle, {Raymond B} and Kevin Leslie and Pettigrew, {Norman M.} and Said, {Jonathan W.} and Corwin, {David J.} and Rickert, {Robert R.} and Roche, {Patrick C.}",
year = "1998",
language = "English (US)",
volume = "122",
pages = "1051--1052",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "12",

}

TY - JOUR

T1 - Extension of useful reagent shelf life beyond manufacturers' recommendations

AU - Tubbs, Raymond R.

AU - Nagle, Raymond B

AU - Leslie, Kevin

AU - Pettigrew, Norman M.

AU - Said, Jonathan W.

AU - Corwin, David J.

AU - Rickert, Robert R.

AU - Roche, Patrick C.

PY - 1998

Y1 - 1998

N2 - Objective. - The College of American Pathologists Cell Markers Committee designed a study to evaluate the use of immunohistochemistry primary antibodies beyond manufacturers' recommended dates. Methods. - Pathologists were asked to save aliquots of primary antibodies during mid-1997 so that by spring 1998 the reagents would be 'outdated' according to manufacturers' recommendations. Three tumors were immunostained both in mid-1997 and early 1998 (using outdated reagents in 1998). Two hundred twenty-one laboratories participated. Patient Samples. - Immunostained materials consisted of an angiomyolipoma immunostained for muscle-specific actin and HMB-45, a melanoma immunostained for S100 protein and HMB-45, and a large cell lymphoma immunostained for common leukocyte antigen and HMB-45. Blocks from the same tumor were used in each instance. Main Outcome Measure. - We compared the immunostaining results as a percentage of laboratories indicating a positive or negative immunohistochemical result between the 1997 and 1998 time points. Results. - Only minor differences were identified for the 221 reporting laboratories in 1998 as compared with those in 1997. Conclusions. - The data suggest review of the Health Care Financing Administration's ruling on extending the useful reagent shelf life beyond manufacturers recommendations. Similar studies using more inherently quantitative methodology are suggested.

AB - Objective. - The College of American Pathologists Cell Markers Committee designed a study to evaluate the use of immunohistochemistry primary antibodies beyond manufacturers' recommended dates. Methods. - Pathologists were asked to save aliquots of primary antibodies during mid-1997 so that by spring 1998 the reagents would be 'outdated' according to manufacturers' recommendations. Three tumors were immunostained both in mid-1997 and early 1998 (using outdated reagents in 1998). Two hundred twenty-one laboratories participated. Patient Samples. - Immunostained materials consisted of an angiomyolipoma immunostained for muscle-specific actin and HMB-45, a melanoma immunostained for S100 protein and HMB-45, and a large cell lymphoma immunostained for common leukocyte antigen and HMB-45. Blocks from the same tumor were used in each instance. Main Outcome Measure. - We compared the immunostaining results as a percentage of laboratories indicating a positive or negative immunohistochemical result between the 1997 and 1998 time points. Results. - Only minor differences were identified for the 221 reporting laboratories in 1998 as compared with those in 1997. Conclusions. - The data suggest review of the Health Care Financing Administration's ruling on extending the useful reagent shelf life beyond manufacturers recommendations. Similar studies using more inherently quantitative methodology are suggested.

UR - http://www.scopus.com/inward/record.url?scp=0032419299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032419299&partnerID=8YFLogxK

M3 - Article

C2 - 9870851

AN - SCOPUS:0032419299

VL - 122

SP - 1051

EP - 1052

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 12

ER -